Last reviewed · How we verify

Prandin — Competitive Intelligence Brief

Prandin (repaglinide) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Glinide [EPC]. Area: Metabolic.

marketed Glinide [EPC] ATP-binding cassette sub-family C member 8 Metabolic Live · refreshed every 30 min

Target snapshot

Prandin (repaglinide) — Novo Nordisk. Repaglinide lowers blood glucose levels by stimulating insulin release from the pancreas through ATP-dependent potassium channel blockade.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Prandin TARGET repaglinide Novo Nordisk marketed Glinide [EPC] ATP-binding cassette sub-family C member 8 1997-01-01
Starlix NATEGLINIDE Novartis marketed Glinide [EPC] Sulfonylurea receptor 1, Kir6.2 2000-01-01
REPAGLINIDE REPAGLINIDE marketed Glinide [EPC] 1997-01-01
MITIGLINIDE MITIGLINIDE marketed mitiglinide Sulfonylurea receptor 1, Kir6.2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Glinide [EPC] class)

  1. · 1 drug in this class
  2. Novartis · 1 drug in this class
  3. Novo Nordisk · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Prandin — Competitive Intelligence Brief. https://druglandscape.com/ci/repaglinide. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: